Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

Background Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Methods Here we describe the rationale and design of the Pha...

Full description

Bibliographic Details
Main Author: Adams, D. (author)
Other Authors: Suhr, O. (author), Dyck, P. (author), Litchy, W. (author), Leahy, R. (author), Chen, J. (author), Gollob, J. (author), Coelho, T. (author)
Format: article
Language:eng
Published: 2018
Subjects:
Patisiran
APOLLO
RNA interference
hATTR amyloidosis
mNIS+7
Methods
Polyneuropathy
Online Access:http://hdl.handle.net/10400.16/2196
Country:Portugal
Oai:oai:repositorio.chporto.pt:10400.16/2196

Internet

http://hdl.handle.net/10400.16/2196

Similar Items